Brokerages Set IonQ, Inc. (NYSE:IONQ) Price Target at $69.92

IonQ, Inc. (NYSE:IONQ) has been given a consensus recommendation of “Moderate Buy” by the fourteen brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $69.9167.

IONQ has been the topic of a number of research analyst reports. Wedbush began coverage on IonQ in a research report on Monday, August 3rd. They set an “outperform” rating and a $75.00 price target on the stock. JPMorgan Chase & Co. lifted their price target on IonQ from $42.00 to $50.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Needham & Company LLC restated a “buy” rating and issued a $65.00 price target on shares of IonQ in a report on Thursday, August 6th. Rosenblatt Securities reaffirmed a “buy” rating and set a $100.00 price objective on shares of IonQ in a research report on Thursday, August 6th. Finally, Wall Street Zen downgraded IonQ from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th.

Insider Buying and Selling at IonQ

In other news, insider John W. Raymond sold 3,815 shares of IonQ stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $55.01, for a total value of $209,863.15. Following the sale, the insider directly owned 80,148 shares in the company, valued at $4,408,941.48. This trade represents a 4.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kathryn K. Chou sold 2,757 shares of IonQ stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $55.02, for a total transaction of $151,690.14. Following the completion of the sale, the director owned 62,608 shares in the company, valued at $3,444,692.16. This trade represents a 4.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 9,329 shares of company stock worth $513,216. Corporate insiders own 0.55% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in IONQ. Archer Investment Corp acquired a new stake in IonQ in the 2nd quarter valued at $25,000. Accent Capital Management LLC grew its holdings in shares of IonQ by 171.8% in the 4th quarter. Accent Capital Management LLC now owns 587 shares of the company’s stock valued at $26,000 after acquiring an additional 371 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of IonQ by 216.5% in the 1st quarter. EverSource Wealth Advisors LLC now owns 959 shares of the company’s stock valued at $28,000 after acquiring an additional 656 shares in the last quarter. PeakShares LLC acquired a new stake in shares of IonQ in the first quarter valued at about $29,000. Finally, EFG International AG bought a new stake in IonQ during the second quarter worth about $30,000. Institutional investors own 41.42% of the company’s stock.

Trending Headlines about IonQ

Here are the key news stories impacting IonQ this week:

• Positive Sentiment: Drug-discovery partnership validates IonQ’s technology. IonQ and QC Ware demonstrated a hybrid quantum-classical chemistry workflow using IonQ’s Forte trapped-ion system through Amazon Braket. The test produced enzyme active-site interaction-energy results within 4% of a benchmark, meeting the chemical-accuracy threshold cited for pharmaceutical research. The announcement expands IonQ’s potential applications beyond general quantum computing and could support future commercial demand. QC Ware and IonQ Demonstrate High-Precision Hybrid Quantum Workflow for Drug Discovery
• Positive Sentiment: IonQ’s platform is being integrated into advanced molecular modeling. QC Ware’s Promethium platform links GPU processing with IonQ Forte hardware, while access through Amazon Braket makes the workflow available through a major cloud-computing channel. This may improve IonQ’s visibility among pharmaceutical and enterprise customers. QC Ware and IonQ Demonstrate High-Precision Hybrid Quantum Workflow for Drug Discovery
• Neutral Sentiment: Analysts see substantial potential upside, but the target is not a new forecast catalyst. IonQ has a reported consensus price target of $69.92, well above the current trading range. However, the company remains unprofitable, with analysts expecting a full-year loss, so investors may require evidence that technical demonstrations translate into recurring revenue. IonQ Receives $69.92 Consensus Price Target from Analysts
• Negative Sentiment: Approaching warrant expiration raises dilution concerns. IonQ’s outstanding public warrants are scheduled to expire on September 30, 2026. Exercise of in-the-money warrants could provide cash to IonQ but increase the share count, potentially pressuring existing shareholders and contributing to near-term volatility. IonQ Warrants Expire September 30 as Investors Watch for Potential Dilution

IonQ Stock Performance

IONQ opened at $37.87 on Wednesday. The company has a fifty day moving average price of $41.98 and a two-hundred day moving average price of $43.48. The firm has a market capitalization of $14.43 billion, a PE ratio of -8.13 and a beta of 3.30. IonQ has a 52 week low of $25.89 and a 52 week high of $84.64.

IonQ (NYSE:IONQ) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.23. The business had revenue of $80.05 million for the quarter, compared to analyst estimates of $66.47 million. IonQ had a negative net margin of 553.27% and a negative return on equity of 22.29%. IonQ’s quarterly revenue was up 286.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.70) EPS. Equities analysts forecast that IonQ will post -2.86 EPS for the current year.

IonQ Company Profile

IonQ, Inc engages in the development of general-purpose quantum computing systems in the United States. It sells access to quantum computers of various qubit capacities. The company makes access to its quantum computers through cloud platforms, such as Amazon Web Services (AWS) Amazon Braket, Microsoft’s Azure Quantum, and Google’s Cloud Marketplace, as well as through its cloud service. It also provides contracts associated with the design, development, and construction of specialized quantum computing hardware systems; maintenance and support services; and consulting services related to co-developing algorithms on quantum computing systems.